---
id: 072
title: Acyclovir Resistance and Nephrotoxicity
category: antimicrobials
subcategory: antivirals_herpes
tags: [acyclovir, resistance, thymidine-kinase, nephrotoxicity, crystal-nephropathy]
difficulty: medium
---

## Question

What causes acyclovir resistance and what is the major toxicity? Use the **"TK-Mutant + Crystal NEPHRO"** mnemonic.

## Answer

### **"TK-Mutant + Crystal NEPHRO" Mnemonic:**

**TK-Mutant (Resistance):**
- **T**hymidine **K**inase deficiency (most common)
- **M**utant TK or DNA polymerase
- **U**sually immunocompromised patients
- **T**reat with foscarnet (bypasses TK)
- **A**ltered DNA polymerase (less common)
- **N**o activation without TK
- **T**ypically HSV/VZV in HIV/transplant

**Crystal NEPHRO:**
- **C**rystallization in renal tubules
- **R**apid IV infusion causes it
- **Y**ield nephrotoxicity (10-20% if dehydrated)
- **S**aline hydration prevents
- **T**ubular obstruction
- **A**cute kidney injury
- **L**ow solubility of drug

**NEPHRO:**
- **N**ephrotoxicity (dose-related)
- **E**nsure hydration (1L NS)
- **P**revent with slow infusion (>1 hour)
- **H**igh-dose IV = highest risk
- **R**enal function monitoring
- **O**bstructive crystal nephropathy

### **Resistance Mechanisms:**

#### **1. TK-Deficient/Altered Mutants (90%):**

**Mechanism:**
- Mutations in viral **thymidine kinase (TK) gene**
- TK-deficient virus → **cannot phosphorylate acyclovir**
- No activation → no antiviral effect

**Clinical Scenario:**
- Immunocompromised patients (HIV, transplant, prolonged therapy)
- Progressive lesions despite acyclovir therapy
- Typically after **prolonged exposure**

#### **2. DNA Polymerase Mutations (10%):**

**Mechanism:**
- Mutations in viral **DNA polymerase gene**
- Acyclovir triphosphate not recognized by mutant enzyme
- Less common than TK mutations

### **Treatment of Resistant HSV/VZV:**

| Drug | Mechanism | Notes |
|------|-----------|-------|
| **Foscarnet** | Inhibits viral DNA polymerase **directly** (no TK needed) | 1st-line for resistant HSV/VZV |
| **Cidofovir** | Inhibits viral DNA polymerase (no TK needed) | Alternative, more toxic |

**Key:** Foscarnet **bypasses TK requirement** → effective against TK-deficient mutants

## Key Points

### **Nephrotoxicity (Major Toxicity):**

**Mechanism:**
- Acyclovir has **low solubility** in urine
- **Crystallizes in renal tubules** → obstructive nephropathy
- Tubular precipitation → acute kidney injury

**Risk Factors:**
- **High-dose IV therapy** (especially 10 mg/kg for HSV encephalitis)
- **Rapid IV infusion** (<1 hour)
- **Volume depletion** (dehydration)
- **Preexisting renal impairment**
- **Concurrent nephrotoxic drugs**

**Incidence:**
- **10-20%** if inadequate hydration
- **<5%** with proper hydration and slow infusion

**Prevention:**

| Strategy | Implementation | Benefit |
|----------|----------------|---------|
| **Adequate hydration** | 1L NS before acyclovir IV | ↓ Crystal formation |
| **Slow IV infusion** | Infuse over **≥1 hour** | Prevents high peak levels |
| **Dose adjustment** | Reduce dose if CrCl <50 | Prevents accumulation |
| **Monitor Cr** | Daily during IV therapy | Catch early |

**Management if AKI occurs:**
- Hold acyclovir temporarily
- IV hydration
- Usually **reversible** with discontinuation

### **Renal Dosing (Acyclovir IV):**

| CrCl (mL/min) | Standard Dose | Adjusted Interval |
|---------------|---------------|-------------------|
| **>50** | 5-10 mg/kg | q8h |
| **25-50** | Same dose | **q12h** |
| **10-25** | Same dose | **q24h** |
| **<10 or HD** | Same dose | **q24h after HD** |

### **Other Side Effects (Rare):**

- **Neurotoxicity** (high doses, renal impairment): confusion, hallucinations, tremors, seizures
- **Phlebitis** (IV administration)
- **Nausea** (oral)
- **Headache**

### **Clinical Pearls:**
- **Resistance rare** in immunocompetent patients
- **TK-deficient mutants** most common resistance mechanism (90%)
- **Foscarnet** for resistant HSV/VZV (bypasses TK requirement)
- **Nephrotoxicity preventable** with hydration + slow infusion
- **Always infuse over ≥1 hour** (never bolus)
- **Valacyclovir** has same resistance patterns (prodrug of acyclovir)
- AKI usually **reversible** with drug discontinuation

## Sources

- [StatPearls NBK542180: Acyclovir 2024]
- [NCBI Books: Antiviral Therapy HSV Resistance]
- [PMC9863155: Optimizing Antiviral Dosing in Immunocompromised]

## Media

N/A
